<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286234</url>
  </required_header>
  <id_info>
    <org_study_id>DK61486 (completed)</org_study_id>
    <secondary_id>R01DK061486</secondary_id>
    <nct_id>NCT00286234</nct_id>
  </id_info>
  <brief_title>Niacin, N-3 Fatty Acids and Insulin Resistance</brief_title>
  <official_title>Niacin, N-3 Fatty Acids and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Dakota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Dakota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to test the effects of two drugs on blood lipids&#xD;
      (cholesterol and triglycerides) and blood sugar (glucose) levels in patients with diabetes or&#xD;
      &quot;pre-diabetes&quot; (both of which have a condition called &quot;insulin-resistance&quot;). These products&#xD;
      are Niaspan (extended release nicotinic acid) and Omacor (omega-3 acid ethyl esters). We&#xD;
      hypothesize that the combination of Niaspan and Omacor will reduce serum triglyceride levels,&#xD;
      increase HDL-cholesterol levels and do so without altering glucose levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The insulin resistance syndrome (IRS) afflicts approximately 25% of the US adult population.&#xD;
      Its principal components include some or all of the following: central obesity, elevated&#xD;
      triglyceride levels, decreased high density lipoprotein cholesterol (HDL-C) levels, a&#xD;
      preponderance of small, dense low density lipoprotein (LDL) particles, hyperglycemia,&#xD;
      hypertension, and increased thrombotic tendency. Subjects with the IRS are at increased risk&#xD;
      for type 2 diabetes and/or coronary heart disease (CHD). While lifestyle changes (diet and&#xD;
      exercise) often improve many of the manifestations of the IRS, pharmacotherapy is often&#xD;
      needed to normalize individual components.&#xD;
&#xD;
      In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in&#xD;
      combination in insulin resistant individuals led to an expected improved the lipid phenotype&#xD;
      (reduced triglycerides, increased HDL-C, and fewer, small, dense LDL particles). What was not&#xD;
      expected, however, was that an important marker of adipose tissue insulin resistance -&#xD;
      meal-induced suppression of free fatty acid (FFA) flux - would be improved as well. Further,&#xD;
      knowing that these agents (given as monotherapy) have been reported to worsen glycemia in&#xD;
      diabetic subjects, we were surprised to find no significant deterioration in glycemic&#xD;
      control. Further preliminary studies in patients with poorly-controlled type 2 diabetes&#xD;
      confirmed the ability of this combination of over-the-counter natural agents to significantly&#xD;
      improve the lipid profile without adverse effects on glycemia.&#xD;
&#xD;
      Our working hypothesis is that excessive FFA flux from adipose tissue raises serum&#xD;
      triglyceride concentrations and leads to other manifestations of the IRS. FFA flux is&#xD;
      chronically elevated in insulin resistant subjects due to the insensitivity (i.e.,&#xD;
      resistance) of their adipocytes to the anti-lipolytic effects of insulin. Released FFA&#xD;
      (especially from visceral adipose depots) stimulate hepatic triglyceride synthesis, leading&#xD;
      to elevated serum triglyceride levels which subsequently contribute to reduced HDL-C and&#xD;
      increased small, dense LDL concentrations. In addition, a high FFA flux can interfere with&#xD;
      whole body glucose disposal. If this hypothesis is true, then interventions that improve&#xD;
      adipocyte insulin sensitivity may be expected to improve a spectrum of risk factors&#xD;
      associated with the insulin resistant state.&#xD;
&#xD;
      Since our preliminary studies support this hypothesis, we propose the following four specific&#xD;
      aims which will be tested in a 4-arm, randomized, placebo-controlled, double blind trial:&#xD;
&#xD;
      Specific Aim 1. To test the hypothesis that n-3 FA and niacin (given singly and in&#xD;
      combination) will enhance insulin-mediated suppression of FFA rate of appearance (Ra; a&#xD;
      surrogate for adipose tissue insulin sensitivity) in insulin resistant subjects.&#xD;
&#xD;
      Specific Aim 2. To test the hypothesis that n-3 FA and niacin (given singly and in&#xD;
      combination) will improve insulin sensitivity in insulin resistant subjects.&#xD;
&#xD;
      Specific Aim 3. To test the hypothesis that n-3 FA and niacin (given singly and in&#xD;
      combination) will reduce VLDL-triglyceride production rates in insulin resistant subjects.&#xD;
&#xD;
      Specific Aim 4. To test the hypothesis that n-3 FA and niacin (given singly and in&#xD;
      combination) will improve the dyslipidemic profile (i.e., reduce serum triglyceride and&#xD;
      small, dense LDL concentrations and elevate HDL-C concentrations) in insulin resistant&#xD;
      subjects.&#xD;
&#xD;
      At the completion of these studies, we expect to have detailed information on the potential&#xD;
      therapeutic efficacy and the kinetic mechanism of action of combined treatment with n-3 FA&#xD;
      and niacin. A better understanding of the action of these agents should lead to a clearer&#xD;
      appreciation of the relationship between FFA flux and insulin resistance, to more effective&#xD;
      therapy for the dyslipidemia of insulin resistance and ultimately to reduced risk for CAD in&#xD;
      this burgeoning patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum TG</measure>
    <time_frame>4 months</time_frame>
    <description>Change From Baseline to 4 Months in Serum Triglycerides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-C</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>Change From Baseline to 4 Months in Serum Non-HDL cholesterol</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dual placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>niaspan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lovaza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 acid ethyl esters</intervention_name>
    <description>4 q qd</description>
    <arm_group_label>3</arm_group_label>
    <other_name>lovaza omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended release niacin</intervention_name>
    <description>2 g qpm</description>
    <arm_group_label>2</arm_group_label>
    <other_name>niaspan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>omacor placebo plus niaspan placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 acid ethyl esters</intervention_name>
    <description>4 g qd</description>
    <arm_group_label>3</arm_group_label>
    <other_name>lovaza omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined treatment</intervention_name>
    <description>omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
    <arm_group_label>4</arm_group_label>
    <other_name>lovaza, omacor</other_name>
    <other_name>niaspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        40 and 69 years of age Male or female (without hormonal cycling as described below) BMI &gt;&#xD;
        25 Fasting serum triglycerides &gt; 150 mg/dL Ratio of TG/HDL-C &gt; 3.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        BMIs &gt; 40 kg/m2 TG &gt; 750 mg/dL HDL-C &lt; 10 mg/dL Presence of other secondary causes of&#xD;
        dyslipidemia or hyperglycemia such as hepatic, renal, thyroid or other endocrine diseases&#xD;
        History of hypersensitivity to niacin or fish oils History of gout, hepatitis, peptic ulcer&#xD;
        or cardiovascular disease Presence of diabetes mellitus, whether controlled by diet or&#xD;
        drugs. (We will eliminate subjects with undiagnosed diabetes by screening for fasting&#xD;
        glucose &gt; 126 mg/dL) Use of any dietary supplements providing more than 50 mg of niacin or&#xD;
        100 mg of n-3 FA Use of any herbal preparations or weight-loss products Taking any&#xD;
        lipid-lowering drugs for at least four weeks prior to screening for the study&#xD;
        Medically-required treatment with nitrates, calcium channel blockers, or adrenergic&#xD;
        blocking agents (per the Niaspan package insert) Hemoglobin &lt; 12 g/dL (owing to the&#xD;
        significant amount of blood being drawn) LDL-C &gt; 145 mg/dL. (This restriction will prevent&#xD;
        the randomization of any subject whose LDL-C levels, if assigned to an n-3 FA group, might&#xD;
        rise by 10% and thus exceed 160 mg/dL) Known substance abuse Participation in a clinical&#xD;
        drug trial anytime during the 30 days prior to screening Anyone whom the investigators&#xD;
        judge to be a poor candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanford Research/USD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Clinic Clinical Research Services</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22892157</url>
    <description>Abstract to Published Paper</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>September 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Dakota</investigator_affiliation>
    <investigator_full_name>William S. Harris, PhD, FAHA, FNLA</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>triglycerides</keyword>
  <keyword>HDL-cholesterol</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>niacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from throughout the Sanford Clinic - Clinical Research Services in Sioux Falls by posted advertisements in public places and at sponsored health fairs.</recruitment_details>
      <pre_assignment_details>68 subjects willing to participate and qualified were subjected to a 6 week single blind run in period where they were given placebo omega-3 and placebo niacin. &quot;Baseline&quot; was defined as values and metrics after this run in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dual Placebo</title>
          <description>Dual placebo&#xD;
placebo: omacor placebo plus niaspan placebo</description>
        </group>
        <group group_id="P2">
          <title>Niaspan</title>
          <description>niaspan&#xD;
extended release niacin: 2 g qpm</description>
        </group>
        <group group_id="P3">
          <title>Lovaza</title>
          <description>lovaza&#xD;
omega-3 acid ethyl esters: 4 q qd</description>
        </group>
        <group group_id="P4">
          <title>Combined Therapy</title>
          <description>combined therapy&#xD;
combined treatment: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dual Placebo</title>
          <description>Dual placebo&#xD;
placebo: omacor placebo plus niaspan placebo</description>
        </group>
        <group group_id="B2">
          <title>Niaspan</title>
          <description>niaspan&#xD;
extended release niacin: 2 g qpm</description>
        </group>
        <group group_id="B3">
          <title>Lovaza</title>
          <description>lovaza&#xD;
omega-3 acid ethyl esters: 4 q qd&#xD;
omega-3 acid ethyl esters: 4 g qd</description>
        </group>
        <group group_id="B4">
          <title>Combined Therapy</title>
          <description>combined therapy&#xD;
combined treatment: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="39" upper_limit="65"/>
                    <measurement group_id="B2" value="49" lower_limit="41" upper_limit="56"/>
                    <measurement group_id="B3" value="44" lower_limit="40" upper_limit="49"/>
                    <measurement group_id="B4" value="48" lower_limit="44" upper_limit="54"/>
                    <measurement group_id="B5" value="46" lower_limit="40" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum TG</title>
        <description>Change From Baseline to 4 Months in Serum Triglycerides</description>
        <time_frame>4 months</time_frame>
        <population>Those subjects with complete data baseline to end</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Placebo</title>
            <description>Dual placebo&#xD;
placebo: omacor placebo plus niaspan placebo</description>
          </group>
          <group group_id="O2">
            <title>Niaspan</title>
            <description>niaspan&#xD;
extended release niacin: 2 g qpm</description>
          </group>
          <group group_id="O3">
            <title>Lovaza</title>
            <description>lovaza&#xD;
omega-3 acid ethyl esters: 4 q qd&#xD;
omega-3 acid ethyl esters: 4 g qd</description>
          </group>
          <group group_id="O4">
            <title>Combined Therapy</title>
            <description>combined therapy&#xD;
combined treatment: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
          </group>
        </group_list>
        <measure>
          <title>Serum TG</title>
          <description>Change From Baseline to 4 Months in Serum Triglycerides</description>
          <population>Those subjects with complete data baseline to end</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233" spread="162"/>
                    <measurement group_id="O2" value="157" spread="52"/>
                    <measurement group_id="O3" value="176" spread="63"/>
                    <measurement group_id="O4" value="156" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL-C</title>
        <description>Change From Baseline to 4 Months in Serum Non-HDL cholesterol</description>
        <time_frame>baseline and 4 months</time_frame>
        <population>all subjects with pre and post treatment data</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Placebo</title>
            <description>Dual placebo&#xD;
placebo: omacor placebo plus niaspan placebo</description>
          </group>
          <group group_id="O2">
            <title>Niaspan</title>
            <description>niaspan&#xD;
extended release niacin: 2 g qpm</description>
          </group>
          <group group_id="O3">
            <title>Lovaza</title>
            <description>lovaza&#xD;
omega-3 acid ethyl esters: 4 q qd&#xD;
omega-3 acid ethyl esters: 4 g qd</description>
          </group>
          <group group_id="O4">
            <title>Combined Therapy</title>
            <description>combined therapy&#xD;
combined treatment: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-C</title>
          <description>Change From Baseline to 4 Months in Serum Non-HDL cholesterol</description>
          <population>all subjects with pre and post treatment data</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="23"/>
                    <measurement group_id="O2" value="155" spread="43"/>
                    <measurement group_id="O3" value="133" spread="34"/>
                    <measurement group_id="O4" value="170" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks of the intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dual Placebo</title>
          <description>Dual placebo&#xD;
placebo: omacor placebo plus niaspan placebo</description>
        </group>
        <group group_id="E2">
          <title>Niaspan</title>
          <description>niaspan&#xD;
extended release niacin: 2 g qpm</description>
        </group>
        <group group_id="E3">
          <title>Lovaza</title>
          <description>lovaza&#xD;
omega-3 acid ethyl esters: 4 q qd&#xD;
omega-3 acid ethyl esters: 4 g qd</description>
        </group>
        <group group_id="E4">
          <title>Combined Therapy</title>
          <description>combined therapy&#xD;
combined treatment: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Harris</name_or_title>
      <organization>Sanford School of Medicine, University of South Dakota</organization>
      <phone>16052716917 ext 2</phone>
      <email>bill@omegaquant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

